WO2001058454A1 - Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor - Google Patents

Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor Download PDF

Info

Publication number
WO2001058454A1
WO2001058454A1 PCT/FI2001/000105 FI0100105W WO0158454A1 WO 2001058454 A1 WO2001058454 A1 WO 2001058454A1 FI 0100105 W FI0100105 W FI 0100105W WO 0158454 A1 WO0158454 A1 WO 0158454A1
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
adrenoceptor
disease
antagonist
selective
Prior art date
Application number
PCT/FI2001/000105
Other languages
French (fr)
Inventor
Siegfried Wurster
Mia Engström
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva-Liisa Savola
Original Assignee
Oy Juvantia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/en
Priority to KR1020027010329A priority Critical patent/KR20020080413A/en
Priority to HU0300032A priority patent/HUP0300032A3/en
Priority to SK1147-2002A priority patent/SK11472002A3/en
Priority to BR0108221-3A priority patent/BR0108221A/en
Priority to IL15101701A priority patent/IL151017A0/en
Priority to JP2001557564A priority patent/JP2003522148A/en
Priority to EEP200200435A priority patent/EE200200435A/en
Priority to AU35510/01A priority patent/AU780802B2/en
Priority to NZ520500A priority patent/NZ520500A/en
Priority to MXPA02007454A priority patent/MXPA02007454A/en
Priority to EP01907585A priority patent/EP1253926A1/en
Priority to PL01357872A priority patent/PL357872A1/en
Priority to CA002399421A priority patent/CA2399421A1/en
Priority to EA200200846A priority patent/EA200200846A1/en
Application filed by Oy Juvantia Pharma Ltd filed Critical Oy Juvantia Pharma Ltd
Priority to UA2002086631A priority patent/UA76946C2/en
Publication of WO2001058454A1 publication Critical patent/WO2001058454A1/en
Priority to IS6476A priority patent/IS6476A/en
Priority to NO20023773A priority patent/NO20023773D0/en
Priority to HRP20020746 priority patent/HRP20020746A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to the use of selective alpha-2B-adrenoceptor antagonists for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals.
  • the present invention also relates to a method for the treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals, by administering to said mammal said selective alpha-2B-adrenoceptor antagonist.
  • the selective alpha- 2B-adrenocep tor antagonists shown in Scheme I below are all previously known.
  • the inventors obtained the compounds A (ordering No AE- 848/34956037), C (ordering No AF-399/36012031) and D (ordering No AH- 034/34347043) from SPECS and BioSPECS B.V., Fleminglaan 16, 2289 CP Rijswijk, The Netherlands.
  • the compounds B (ordering No 653716) and E (ordering No 569063) were supplied by ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127.
  • alpha-2B-adrenoceptors mediate vascular contractions. Therefore, alpha-2B -antagonists are useful in the treatment or prevention of diseases involving vascular contraction. It has also been found that there is a genetic polymorphism in the alpha-2B-adrenoceptor gene at certain individuals. It has been observed that the alpha-2B-adrenoceptor protein at some subjects has a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297-309), in an acid trech of 17 amino acids, located in the third intracellular loop of the receptor polypeptide (Heinonen et al., 1999).
  • this invention relates to the use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B -adrenoceptor in a mammal.
  • said antagonist is a compound selected from the group consisting of compound A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
  • This invention relates also to a method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal, said method comprising administering to said mammal an effective amount of a selective alpha-2B- adrenoceptor antagonist, wherein said antagonist is a compound selected from the group consisting of compound A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
  • Alpha-2B-adrenoceptor antagonists are useful in the treatment and/or prevention of many diseases.
  • D/D genotype Individuals having a deletion in the alpha-2B-adrenoceptor protein (Heinonen et al., 1999), particularly the deletion/deletion genotype (D/D genotype) is an important target group which benefits from administration of selective alpha-2B-adrenoceptor antagonists.
  • alpha-2B-adrenoceptors are believed to be involved in the pathogenesis of a significant fraction of all cases of AMI, especially in subjects with the D/D genotype, but also in I/D and I/I subjects (I means "insertion” and stands for the "normal” allele).
  • alpha-2B -adrenoceptor antagonists as disclosed in this invention would be particularly useful in the treatment or prevention of coronary heart diseases. As examples can be mentioned
  • alpha-2B -adrenoceptor dependent vasoconstriction is a causative factor in some cases of AMI, then antagonism of these receptors should restore coronary circulation and reduce the ischemic myocardial damage.
  • Vasoconstriction is a key factor in the pathogenesis of Prinzmetal's angina, and an alpha-2B- adrenoceptor antagonist may resolve and prevent attacks.
  • An alpha-2B -adrenoceptor antagonist will help to alleviate the vasoconstrictive component in all types of CHD, providing both symptomatic relief and protection from AMI.
  • a general reduction in vascular tone will contribute to this by reducing venous return, cardiac workload and oxygen consumption (a nitrate-type effect; see below).
  • the alpha-2B -adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of essential hypertension, especially in subjects with increased sympathetic activity and a hyperdynamic circulatory system.
  • alpha-2B- adrenoceptors mediate vascular contraction.
  • an antagonist should reduce blood pressure.
  • alpha-2B-nonselective alpha-2- adrenoceptor antagonists because antagonism of alpha-2A-adrenoceptors increases sympathetic outflow, cardiac output and blood pressure.
  • alpha-2-adreoceptor agonists caused an accentuated hypertensive response and no hypotension (MacMillan et al., 1996).
  • An alpha- 2B-adrenoceptor antagonist is postulated to have favourable effects in hypertensive subjects through their effects on renal function, muscle blood flow, and also on vascular resistance in other vascular beds.
  • the anti-AMI effect of such a drug will be an additional benefit, as hypertension is a significant risk factor for AMI. This protection is due to three factors: 1) a reduction in systemic blood pressure, 2) decreased risk of coronary vasoconstriction, and 3) a nitrate-like effect on venous return, myocardial workload and oxygen consumption.
  • alpha-2B-adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of other vascular diseases. Specifically, benefits can be expected in the treatment or prevention of
  • alpha-2B -adrenoceptor antagonists disclosed in this invention are also useful in anesthesia and analgesia to potentiate the clinical efficacy of alpha-2-adrenoceptor agonists which are not selective for the alpha-2B-adrenoceptor subtype.
  • a simultaneously administered alpha-2B -adrenoceptor antagonist will allow the use of larger doses of said agonists, up to anesthetic dose levels which have not previously been possible in man, only in veterinary anesthetic practice.
  • the affinity of test compounds for the three human 2 -adrenoceptor subtypes was determined in competition binding assays with H-rauwolscine.
  • the biological material for these experiments consisted of membranes from Shionogi SI 15 cells stably transfected with either of the three human ⁇ 2 subtypes (Marjamaki et al. 1992). Membrane (5-10 ⁇ g of total protein per sample) and 1 nM - 2 nM H-rauwolscine (specific activity 78 Ci/mmol) were incubated in 50 mM KH 2 P0 4 , pH 7.5 with 6 concentrations of the compounds. Each concentration was run in duplicate.
  • Nonspecific binding was defined by 100 ⁇ M oxymetazoline and corresponded to 5 - 15% of total binding. After 30 min at room temperature, incubations were terminated by rapid vacuum filtration through GF/B glass fiber filter and three 5 ml washes with icecold incubation buffer. The filters were then dried, impregnated with scintillate and their radioactivity was measured by scintillation counting. The analysis of the experiments was carried out by nonlinear least square curve fitting. Experimentally determined IC50 values were converted to Ki's by making use of the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experiments were repeated a minimum of three times.
  • the affinity for rat neocortical ⁇ adrenoceptors was determined in competition binding assays with 3 H-prazosin.
  • the biological material for these assays consisted of membranes from rat neocortex. Membrane suspensions (100-200 ⁇ g of total protein per sample) and 0.2 nM-0.25nM of ⁇ -prazosin (specific activity 74 Ci/mmol) were incubated with 6 concentrations of compounds in a total volume of 0.25 ml (50 mM Tris pH 7.7 at 25°C). Each concentration was run in duplicate. Nonspecific binding was defined by 10 ⁇ M phentolamine methanesulfonate and corresponded to 25-30 % of total binding.
  • Antagonist potencies were determined as the ability of test compounds to competitively inhibit epinephrine-stimulated 35 S-GTP ⁇ S binding to G proteins (Tian et al., 1993; Wieland and Jakobs, 1994; Jasper et al., 1998) in membranes of CHO cells stably transfected with one of the three human 2 subtypes (Pohjanoksa et al., 1997; Marjamaki et al, 1998).
  • Membranes (2-6 ⁇ g of protein per sample) and 12 concentrations of test compound were preincubated for 30 min with a fixed concentration fo epinephrine (5 ⁇ M for 2A assume 15 ⁇ M for 2B , 5 ⁇ M for 2C ) in 50 mM Tris, 5 mM MgCl 2 , 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 ⁇ M GDP, 30 ⁇ M ascorbic acid, pH 7.4 at room temperature. Binding of radiolabel was started by the addition of trace amounts of 35 S-GTP ⁇ S (0.08 nM- 0.15 nM, specific activity 1250 Ci/mmol) to the incubation mixture.
  • the alpha-2B -adrenoceptor antagonist as disclosed in Scheme I or its pharmaceutically acceptable salt can be administered by various routes.
  • the suitable administration forms include, for example, oral formulations; parenteral injections including intravenous, intramuscular, intradermal and subcutanous injections; transdermal or rectal administration forms.
  • the required dosage of the compounds of the alpha-2B-adrenoceptor antagonist will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed.
  • the suitable dose varies in the range 5 ⁇ g to 100 mg per kg body weight and day for an adult person.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal. Said antagonist is a compound selected from the group consisting of compounds A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound. The present invention also relates to a method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal. Said method comprises administering to said mammal an effective amount of said selective alpha-2B-adrenoceptor antagonist.

Description

COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF A DISEASE MEDIATED BY THE ALPHA-2B-ADRENOCEPTOR
The present invention relates to the use of selective alpha-2B-adrenoceptor antagonists for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals. The present invention also relates to a method for the treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals, by administering to said mammal said selective alpha-2B-adrenoceptor antagonist.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
The selective alpha- 2B-adrenocep tor antagonists shown in Scheme I below are all previously known. The inventors obtained the compounds A (ordering No AE- 848/34956037), C (ordering No AF-399/36012031) and D (ordering No AH- 034/34347043) from SPECS and BioSPECS B.V., Fleminglaan 16, 2289 CP Rijswijk, The Netherlands. The compounds B (ordering No 653716) and E (ordering No 569063) were supplied by ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127.
It is known that alpha-2B-adrenoceptors mediate vascular contractions. Therefore, alpha-2B -antagonists are useful in the treatment or prevention of diseases involving vascular contraction. It has also been found that there is a genetic polymorphism in the alpha-2B-adrenoceptor gene at certain individuals. It has been observed that the alpha-2B-adrenoceptor protein at some subjects has a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297-309), in an acid trech of 17 amino acids, located in the third intracellular loop of the receptor polypeptide (Heinonen et al., 1999).
OBJECTS AND SUMMARY OF THE INVENTION
It has now been found that the compounds selected from the group consisting of compound A, B, C, D and E, the formulae of which are disclosed in Scheme I, are selective alpha-2B-adrenoceptor antagonists.
Thus, this invention relates to the use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B -adrenoceptor in a mammal. According to the invention, wherein said antagonist is a compound selected from the group consisting of compound A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
This invention relates also to a method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal, said method comprising administering to said mammal an effective amount of a selective alpha-2B- adrenoceptor antagonist, wherein said antagonist is a compound selected from the group consisting of compound A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
DETAILED DESCRIPTION OF THE INVENTION
Alpha-2B-adrenoceptor antagonists are useful in the treatment and/or prevention of many diseases.
Individuals having a deletion in the alpha-2B-adrenoceptor protein (Heinonen et al., 1999), particularly the deletion/deletion genotype (D/D genotype) is an important target group which benefits from administration of selective alpha-2B-adrenoceptor antagonists.
It has been found that in a population-based cohort of Finnish middle-aged men that subjects with a D/D genotype of the alpha-2B -adrenoceptor gene have a significantly elevated risk for acute myocardial infarction (AMI) in a five-year follow-up study. The risk for AMI was increased in subjects who had no previously diagnosed coronary heart disease (CHD) at the study outset. Therefore, it has been postulated that the D/D genotype is related to an impaired capacity to down-regulate alpha-2B -adrenoceptor function during sustained receptor activation. Therefore, alpha-2B-adrenoceptors are believed to be involved in the pathogenesis of a significant fraction of all cases of AMI, especially in subjects with the D/D genotype, but also in I/D and I/I subjects (I means "insertion" and stands for the "normal" allele).
The alpha-2B -adrenoceptor antagonists as disclosed in this invention would be particularly useful in the treatment or prevention of coronary heart diseases. As examples can be mentioned
a) Acute AMI
If alpha-2B -adrenoceptor dependent vasoconstriction is a causative factor in some cases of AMI, then antagonism of these receptors should restore coronary circulation and reduce the ischemic myocardial damage.
b) Unstable angina pectoris
An alpha-2B -adrenoceptor antagonist will relieve the vasoconstrictive component in the sustained ischemic episode, thus alleviating the symptoms and preventing AMI. c) Prinzmetal's variant form of angina pectoris
Vasoconstriction is a key factor in the pathogenesis of Prinzmetal's angina, and an alpha-2B- adrenoceptor antagonist may resolve and prevent attacks.
d) Other forms of chronic angina pectoris and CHD
An alpha-2B -adrenoceptor antagonist will help to alleviate the vasoconstrictive component in all types of CHD, providing both symptomatic relief and protection from AMI. A general reduction in vascular tone will contribute to this by reducing venous return, cardiac workload and oxygen consumption (a nitrate-type effect; see below).
e) Prevention of restenosis after coroary angioplasty in cases where vasoconstriction plays a role in restenosis.
Furhermore, the alpha-2B -adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of essential hypertension, especially in subjects with increased sympathetic activity and a hyperdynamic circulatory system.
In the study mentioned above, the D/D variant of the alpha-2B-adrenoceptor gene was not clearly associated with blood pressure. The inventors believe that this was due to two main factors, 1) antihypertensive treatment, and 2) complex regulation of systemic blood pressure. In another study (Heinonen et al.), it was observed that the D/D genotype was associated with reduced basal metabolic rate and reduced heart rate. These associations probably reflect increased vascular resistance in these subjects. In transgenic mice with targeted inactivation of the alpha-2B -adrenoceptor gene, intravenously administered alpha-2-adrenoceptor agonists fail to induce the characteristic blood pressure elevation which is seen in normal animals and also in humans after large doses of such drugs (Link et al., 1996). The hypotensive effect of these drugs was markedly accentuated. This demonstrates that alpha- 2B- adrenoceptors mediate vascular contraction. Thus, an antagonist should reduce blood pressure. This effect has not been seen with alpha-2B-nonselective alpha-2- adrenoceptor antagonists, because antagonism of alpha-2A-adrenoceptors increases sympathetic outflow, cardiac output and blood pressure. In mice with dysfunctional alpha- 2A-adrenoceptors, alpha-2-adreoceptor agonists caused an accentuated hypertensive response and no hypotension (MacMillan et al., 1996).
An alpha- 2B-adrenoceptor antagonist is postulated to have favourable effects in hypertensive subjects through their effects on renal function, muscle blood flow, and also on vascular resistance in other vascular beds. The anti-AMI effect of such a drug will be an additional benefit, as hypertension is a significant risk factor for AMI. This protection is due to three factors: 1) a reduction in systemic blood pressure, 2) decreased risk of coronary vasoconstriction, and 3) a nitrate-like effect on venous return, myocardial workload and oxygen consumption.
Moreover, the alpha-2B-adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of other vascular diseases. Specifically, benefits can be expected in the treatment or prevention of
- vasoconstriction and hypoxic brain damage subsequent to subarachnoid haemorrhage,
- migraine,
- Raynaud's disease and cold intolerance,
- pre-eclampsia,
- male erectile dysfynction, and - obesity and the metabolic syndrome. The last mentioned effect is due to the fact that reduced muscle blood flow and reduced basal metabolic rate contribute to the development of obesity and hypertension. An alpha-2B -adrenoceptor antagonist will, by increasing the muscle blood flow, increase energy expenditure and shift the caloric balance to a favourable direction.
The alpha-2B -adrenoceptor antagonists disclosed in this invention are also useful in anesthesia and analgesia to potentiate the clinical efficacy of alpha-2-adrenoceptor agonists which are not selective for the alpha-2B-adrenoceptor subtype. By blocking the vasoconstriction induced by these agonists, a simultaneously administered alpha-2B -adrenoceptor antagonist will allow the use of larger doses of said agonists, up to anesthetic dose levels which have not previously been possible in man, only in veterinary anesthetic practice.
EXPERIMENTAL SECTION
Binding affinity human alpha-2-adrenoceptor
The affinity of test compounds for the three human 2-adrenoceptor subtypes (cc2A, α2B and α2C) was determined in competition binding assays with H-rauwolscine. The biological material for these experiments consisted of membranes from Shionogi SI 15 cells stably transfected with either of the three human α2 subtypes (Marjamaki et al. 1992). Membrane (5-10 μg of total protein per sample) and 1 nM - 2 nM H-rauwolscine (specific activity 78 Ci/mmol) were incubated in 50 mM KH2P04, pH 7.5 with 6 concentrations of the compounds. Each concentration was run in duplicate. Nonspecific binding was defined by 100 μM oxymetazoline and corresponded to 5 - 15% of total binding. After 30 min at room temperature, incubations were terminated by rapid vacuum filtration through GF/B glass fiber filter and three 5 ml washes with icecold incubation buffer. The filters were then dried, impregnated with scintillate and their radioactivity was measured by scintillation counting. The analysis of the experiments was carried out by nonlinear least square curve fitting. Experimentally determined IC50 values were converted to Ki's by making use of the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experiments were repeated a minimum of three times.
Table 1 : Binding affinities on human -adrenoceptor subtypes
Data is presented as Ki's in nM (Mean ± SEM), n = 3 unless indicated otherwise
Figure imgf000008_0001
Binding affinity rat cortical a adrenoceptor
The affinity for rat neocortical α adrenoceptors was determined in competition binding assays with 3H-prazosin. The biological material for these assays consisted of membranes from rat neocortex. Membrane suspensions (100-200 μg of total protein per sample) and 0.2 nM-0.25nM of Η-prazosin (specific activity 74 Ci/mmol) were incubated with 6 concentrations of compounds in a total volume of 0.25 ml (50 mM Tris pH 7.7 at 25°C). Each concentration was run in duplicate. Nonspecific binding was defined by 10 μM phentolamine methanesulfonate and corresponded to 25-30 % of total binding. After 30 min at room temperature, incubations was terminated by rapid filtration through GF/B glass-fiber filter mats and three washes with ice-cold 10 mM Tris (pH 7.7 at 4°C). After drying, a solid scintillate was melted onto the filter mats, and their radioactivity was measured by scintillation counting.
Result
At concentrations of up to 30 μM, compound A caused insufficient displacement of 3H-prazosin to allow the estimate of an IC50 value. It is therefore concluded that the IC50 and the Ki of compound A must be >30 000 nM.
Antagonist activity on human 2-adrenoceptor subtypes
Antagonist potencies were determined as the ability of test compounds to competitively inhibit epinephrine-stimulated 35S-GTPγS binding to G proteins (Tian et al., 1993; Wieland and Jakobs, 1994; Jasper et al., 1998) in membranes of CHO cells stably transfected with one of the three human 2 subtypes (Pohjanoksa et al., 1997; Marjamaki et al, 1998). Membranes (2-6 μg of protein per sample) and 12 concentrations of test compound were preincubated for 30 min with a fixed concentration fo epinephrine (5 μM for 2A„ 15 μM for 2B, 5 μM for 2C) in 50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 μM GDP, 30 μM ascorbic acid, pH 7.4 at room temperature. Binding of radiolabel was started by the addition of trace amounts of 35S-GTPγS (0.08 nM- 0.15 nM, specific activity 1250 Ci/mmol) to the incubation mixture. After an additional 60 min at room temperature, the incubation was terminated by rapid vacuum filtration through glass fiber filter. Filters were washed three times with 5 ml icecold wash buffer (20 mM Tris, 5 mM MgCl2, 1 mM EDTA pH 7.4 at room temperature), dried and counted for radioactivity in a scintiallation counter. Analysis of experiments was carried out by nonlinear least square fitting. Experiments were repeated at least three times. Table 2: Antagonist effect of compound A and compound B on the human α2- adrenoceptor subtypes
Data is presented as KB's in nM (Mean ± SEM), n is a minimum of three experiments.
Figure imgf000010_0001
* only incomplete dose-response curves could be obtained, KB numbers are minimum estimates
For the purpose of the invention, the alpha-2B -adrenoceptor antagonist as disclosed in Scheme I or its pharmaceutically acceptable salt can be administered by various routes. The suitable administration forms include, for example, oral formulations; parenteral injections including intravenous, intramuscular, intradermal and subcutanous injections; transdermal or rectal administration forms. The required dosage of the compounds of the alpha-2B-adrenoceptor antagonist will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed. The suitable dose varies in the range 5 μg to 100 mg per kg body weight and day for an adult person.
It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive. Scheme I
Figure imgf000011_0001
REFERENCES
Cheng, Y., and Prusoff, W.H., 1973. Biochem. Pharmacol. 22: 3099
Jasper, J.R., Lesnick, J.D., Chang, L.K., Yamanashi, S.S., Chang, T.C., Hsu,
S.A.O., Daunt, D.A., Bonhaus, D.W., and Egen, R.M., 1998. Biochem. Pharmacol. 55: 1035
Marjamaki, A., Ala-Uotila, S., Luomala, K.. Perala, M., Jansson, C, Jalkanen, M., Regan, J.W., and Scheinin, M., 1992. Biochem. Biophys. Acta 1134: 169
Marjamaki, A., Pihlavisto, M., Cockcroft, V., Heinonen, P., Savola, J.-M., and Scheinin, M., 1998. Mol. Pharmacol. 53: 370
Pohjanoksa, K., Jansson, CC, Luomala, K.. Marjamaki, A., Savola, J.-M., and Scheinin, M, 1997. Eur. J. Pharmacol. 35: 53
Tian, W.-N., Duzic, E., Lanier, S.M., and Deth, R.C., 1993. Mol. Pharmacol. 45: 524
Wieland, T., and Jakobs, K.H., 1994. Meth. Enzymol. 237: 3
Heinonen et al.1999, The Journal of Clinical Endocrinology & Metabolism, 84:2429
Link R E et al., 1996, Science 273:803
MacMillan L B et al., 1996, Science 273:801

Claims

1. Use of a selective alpha-2B-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation for the treatment or prevention of a disease mediated by the alpha-2B -adrenoceptor in a mammal, wherein said antagonist is a compound selected from the group consisting of compounds A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
2. The use according to claim 1, wherein the disease is a coronary heart disease (CHD).
3. The use according to claim 2, wherein the disease is
- acute myocardial infarction (AMI),
- unstable angina pectoris,
- Prinzmetal's variant form of angina pectoris, - other forms of chronic angina pectoris and CHD, or - restenosis after coronary angioplasty.
4. The use according to claim 1, wherein the disease is essential hypertension.
5. The use according to claim 1, wherein the disease is a vascular disease, which is
- vasoconstriction or hypoxic brain damage subsequent to subarachnoid hemorrhage,
- migraine,
- Raynaud's disease or cold intolerance, - pre-eclampsia,
- male erectile dysfunction, or
- obesity.
6. Use of a selective alpha-2B -adrenoceptor antagonist for the manufacture of a pharmaceutical preparation for potentiating the clinical efficacy of an anesthetic and/or analgetic alpha-2-adrenoceptor agonist, said agonist not being selective for the alpha-2B -adrenoceptor subtype.
7. A method for the treatment or prevention of a disease mediated by the alpha-2B- adrenoceptor in a mammal, said method comprising administering to said mammal an effective amount of a selective alpha-2B -adrenoceptor antagonist, wherein said antagonist is a compound selected from the group consisting of compounds A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound.
8. The method according to claim 7, wherein the disease is a coronary heart disease (CHD).
9. The method according to claim 7, wherein the disease is
- acute myocardial infarction (AMI),
- unstable angina pectoris,
- Prinzmetal's variant form of angina pectoris, - other forms of chronic angina pectoris and CHD, or
- restenosis after coronary angioplasty.
10. The method according to claim 7, wherein the disease is essential hypertension.
11. The method according to claim 7, wherein the disease is a vascular disease, which is
- vasoconstriction or hypoxic brain damage subsequent to subarachnoid haemorrhage,
- migraine,
- Raynaud's disease or cold intolerance,
- pre-eclampsia,
- male erectile dysfunction, or
- obesity.
12. The method according to claim 7, wherein said alpha-2B-adrenoceptor antagonist is administered to a mammal to potentiate the clinical efficacy of an anesthetic and/or analgetic alpha-2-adrenoceptor agonist, said agonist not being selective for the alpha- 2B -adrenoceptor subtype.
13. The method according to claim 7, wherein said alpha-2B-adrenoceptor antagonist is administered to an individual having a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297-309), in an acid stretch of 17 amino acids, located in the third intracellular loop of the receptor polypeptide.
14. The method according to claim 13 wherein said individual is a deletion/deletion genotype.
PCT/FI2001/000105 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor WO2001058454A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NZ520500A NZ520500A (en) 2000-02-11 2001-02-07 Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor
EA200200846A EA200200846A1 (en) 2000-02-11 2001-02-07 CONNECTIONS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES MEDIATED BY ALPHA-2B-ADRENOCEPTOR
SK1147-2002A SK11472002A3 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
BR0108221-3A BR0108221A (en) 2000-02-11 2001-02-07 Use of a selective alpha-2b-adrenoceptor antagonist for the manufacture of a pharmaceutical preparation and method for treating or preventing an alpha-2b-adrenoceptor-mediated disease in a mammal
IL15101701A IL151017A0 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
JP2001557564A JP2003522148A (en) 2000-02-11 2001-02-07 Compounds useful for treating or preventing diseases mediated by alpha-2B-adrenergic receptor
EEP200200435A EE200200435A (en) 2000-02-11 2001-02-07 Selective alpha-2B adrenoceptor antagonists and their use
EP01907585A EP1253926A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
MXPA02007454A MXPA02007454A (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha 2b adrenoceptor.
KR1020027010329A KR20020080413A (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
AU35510/01A AU780802B2 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
PL01357872A PL357872A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
CA002399421A CA2399421A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
HU0300032A HUP0300032A3 (en) 2000-02-11 2001-02-07 Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
UA2002086631A UA76946C2 (en) 2000-02-11 2001-07-02 Use of substance for treatment or prevention of diseases mediated by alpha-2b-adrenoreceptor (variants) and method for treating such diseases
IS6476A IS6476A (en) 2000-02-11 2002-07-19 Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors
NO20023773A NO20023773D0 (en) 2000-02-11 2002-08-09 Compounds useful for treating or preventing a disease mediated by alpha-2B adrenoceptor
HRP20020746 HRP20020746A2 (en) 2000-02-11 2002-09-11 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
US60/182,021 2000-02-11
FI20000303 2000-02-14
FI20000303A FI20000303A0 (en) 2000-02-14 2000-02-14 Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease

Publications (1)

Publication Number Publication Date
WO2001058454A1 true WO2001058454A1 (en) 2001-08-16

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Country Status (22)

Country Link
EP (1) EP1253926A1 (en)
JP (1) JP2003522148A (en)
KR (1) KR20020080413A (en)
AU (1) AU780802B2 (en)
BR (1) BR0108221A (en)
CA (1) CA2399421A1 (en)
CZ (1) CZ20022884A3 (en)
EA (1) EA200200846A1 (en)
EE (1) EE200200435A (en)
GE (1) GEP20043356B (en)
HR (1) HRP20020746A2 (en)
HU (1) HUP0300032A3 (en)
IL (1) IL151017A0 (en)
IS (1) IS6476A (en)
MX (1) MXPA02007454A (en)
MY (1) MY133957A (en)
NO (1) NO20023773D0 (en)
NZ (1) NZ520500A (en)
PL (1) PL357872A1 (en)
SK (1) SK11472002A3 (en)
WO (1) WO2001058454A1 (en)
YU (1) YU59102A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008387A1 (en) * 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
US6767909B2 (en) 2001-07-20 2004-07-27 Oy Juvantia Pharma Ltd. Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604398A (en) * 1984-06-28 1986-08-05 John Wyeth & Brother Limited Benzoquinolizine derivatives, and their use as α2 adrenoceptor antagonistic agents
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604398A (en) * 1984-06-28 1986-08-05 John Wyeth & Brother Limited Benzoquinolizine derivatives, and their use as α2 adrenoceptor antagonistic agents
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008387A1 (en) * 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
US6767909B2 (en) 2001-07-20 2004-07-27 Oy Juvantia Pharma Ltd. Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor

Also Published As

Publication number Publication date
AU3551001A (en) 2001-08-20
IS6476A (en) 2002-07-19
EP1253926A1 (en) 2002-11-06
EE200200435A (en) 2003-12-15
BR0108221A (en) 2003-03-05
HRP20020746A2 (en) 2004-12-31
NZ520500A (en) 2005-01-28
HUP0300032A2 (en) 2003-05-28
CA2399421A1 (en) 2001-08-16
SK11472002A3 (en) 2003-02-04
IL151017A0 (en) 2003-02-12
KR20020080413A (en) 2002-10-23
JP2003522148A (en) 2003-07-22
GEP20043356B (en) 2004-04-13
NO20023773L (en) 2002-08-09
PL357872A1 (en) 2004-07-26
MY133957A (en) 2007-11-30
EA200200846A1 (en) 2002-12-26
CZ20022884A3 (en) 2003-02-12
YU59102A (en) 2005-11-28
MXPA02007454A (en) 2004-08-23
NO20023773D0 (en) 2002-08-09
HUP0300032A3 (en) 2006-01-30
AU780802B2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Hayashi et al. Alpha2 adrenoceptor agonists and anaesthesia
Traish et al. Role of alpha adrenergic receptors in erectile function
Zhuo et al. Intracellular ANG II induces cytosolic Ca2+ mobilization by stimulating intracellular AT1 receptors in proximal tubule cells
JP5925121B2 (en) Etomidate analogs that do not inhibit corticosteroid synthesis
Mizobe et al. α2-Adrenoceptor agonists and anesthesia
JP2010514696A (en) Reduction of cardiovascular symptoms
Molderings et al. Imidazoline binding sites and receptors in cardiovascular tissue
Gentili et al. Agonists and antagonists targeting the different α2-adrenoceptor subtypes
ZA200502744B (en) Alpha 3B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration.
US6664397B1 (en) Use of (+)mefloquine for the treatment of malaria
TW445147B (en) Pharmaceutical composition for preventing and treating postischemic renal failure and for protecting the ischemic kidney, comprising an AT1-receptor antagonist
US6521632B2 (en) Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
WO2022095461A1 (en) Compound for specifically enhancing spatial coupling degree of trpv4-kca2.3 complex and use thereof
Hegde et al. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties
Creagh et al. Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate
EP1253926A1 (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
TW200817401A (en) KW-3902 conjugates that do not cross the blood-brain barrier
US6767909B2 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor
US20060293359A1 (en) Methods and compositions for the treatment of diabetes
Miyazawa et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
JP2004535467A (en) Compounds useful for treating or preventing diseases mediated by α-2B-adrenergic receptors
Salonen et al. Clinical interactions with alpha-2-adrenergic agonists in anesthetic practice
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
Goldman et al. Recent inventions on receptor tyrosine kinase RET modulation
NAGATOMO et al. Effect of 3-[2-[4-(o-Methoxyphenyl)-1-piperazinyl] ethyl]-2, 4 (1H, 3H)-quinazolinedione Monohydrochloride (SGB-1534), an Anthihypertensive Agent, on 3H-Prazosin and 3H-p-Aminoclonidine Binding to α1-and α2-Adrenoceptors in Dog Brain and Arta

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-591/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001907585

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/05835

Country of ref document: ZA

Ref document number: 200205835

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 151017

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007454

Country of ref document: MX

Ref document number: 520500

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 35510/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 557564

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11472002

Country of ref document: SK

Ref document number: 2399421

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027010329

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2002-2884

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200200846

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20020618

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020746A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020027010329

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001907585

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-2884

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 520500

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520500

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 35510/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2001907585

Country of ref document: EP